| CTRI Number |
CTRI/2025/08/093745 [Registered on: 27/08/2025] Trial Registered Prospectively |
| Last Modified On: |
20/08/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Ayurveda |
| Study Design |
Randomized, Parallel Group, Multiple Arm Trial |
|
Public Title of Study
|
This study aims to develop and standardize a user-friendly Ayurvedic device called the Dhuma Yantra for delivering (Dhuma Nasya), and to efficacy of Dhuma Nasya with Prototype, Navan Nasya, and classical Dhuma Nasya in the management of Ardhavabhedaka (Migraine) |
|
Scientific Title of Study
|
Development And Validation Of Dhuma Yantra And Its Comparative Clinical Evaluation With Navan Nasya And Dhuma Nasya With Classical Method In Ardhavabhedaka (Migraine): A Randomized Controlled Trial |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
DR AJAY BALAUT |
| Designation |
PG SCHOLAR |
| Affiliation |
All India Institute of Ayurveda |
| Address |
OPD No. 6, Department of panchakarma, Ground floor, Hospital Block, All India Institute of
Ayurveda, Gautampuri, Sarita Vihar, New Delhi
New Delhi DELHI 110076 India |
| Phone |
9315602657 |
| Fax |
|
| Email |
ajaybalaut@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Santosh Kumar Bhatted |
| Designation |
Professor |
| Affiliation |
All India Institute of Ayurveda |
| Address |
Room no.703, Department of Panchakarma, Academic Block, All
India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi
New Delhi DELHI 110076 India |
| Phone |
9414048459 |
| Fax |
|
| Email |
santoshbhatted@rediffmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Santosh Kumar Bhatted |
| Designation |
Professor |
| Affiliation |
All India Institute of Ayurveda |
| Address |
Room no.703, Department of Panchakarma, Academic Block, All
India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi
New Delhi DELHI 110076 India |
| Phone |
9414048459 |
| Fax |
|
| Email |
santoshbhatted@rediffmail.com |
|
|
Source of Monetary or Material Support
|
| All India Institute of Ayurveda Gautampuri, Sarita Vihar, New Delhi 110076 |
|
|
Primary Sponsor
|
| Name |
All India Institute of Ayurveda |
| Address |
All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| DR AJAY BALAUT |
ALL INDIA INSTITUTE OF AYURVEDA HOSPITAL |
Department of
Panchakarma, OPD no.
6, Gautampuri, Sarita
Vihar, New
Delhi-110076
South West
DELHI New Delhi DELHI |
09315602657
ajaybalaut@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition:G439||Migraine, unspecified. Ayurveda Condition: ARDHAVABEDAKAH, |
|
|
Intervention / Comparator Agent
|
| sno | Intervention/Comparator | Type | Drug-Type | Procedure Name | Details | | 1 | Comparator Arm | Procedure | - | dhUmapAnam, धूमपानम् | (Procedure Reference: charak samhita , Procedure details: 3 or 4 sets of 3 inhalations and exhalations with shirovirechanadi dhumvarti with classical method. ) (1) Medicine Name: shirovirechanadi dhumvarti, Reference: charak samhita , Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 4(NA), Frequency: od, Duration: 15 Days | | 2 | Comparator Arm | Procedure | - | nasyam/ nastam, नस्यम्/ नस्तम् | (Procedure Reference: charak samhita , Procedure details: Nasya for group A with anu taila 3 drops each nostril ) (1) Medicine Name: anu taila , Reference: charak samhita , Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 3(drops), Frequency: od, Duration: 15 Days | | 3 | Intervention Arm | Procedure | - | dhUmapAnam, धूमपानम् | (Procedure Reference: charak samhita , Procedure details: 3 – 4 sets of 3 inhalations and exhalations with shirovirechanadi dhumvarti using prototype ) (1) Medicine Name: shirovirechanadi dhumvarti, Reference: charak samhita , Route: Nasal, Dosage Form: Bindu/ Drops/ Spray (Karna/ Nasa/ Netra/ Mukha), Dose: 4(NA), Frequency: od, Duration: 15 Days |
|
|
|
Inclusion Criteria
|
| Age From |
17.00 Year(s) |
| Age To |
70.00 Year(s) |
| Gender |
Both |
| Details |
a) Age : between 17 to 70 years
b) Gender: both
c) Socio-economic status: all
d) Willing to participate in the study.
e) Patients with the classical picture of ARDHAVBHEDAKA [Migraine] will be selected irrespective of Sex, Religion, and Profession.
|
|
| ExclusionCriteria |
| Details |
(1) Patients who were not eligible for NASYA as per Ayurvedic Texts.
(2) Age less than 16 years and greater than 70 years.
(3) Referred pain in one half of the head due to disorders of the Eye, Ear, Nose, Throat, Teeth, etc., was excluded
(4) Patient having Familial Hemiplegic Migraine (FHM), Complicated Migraine, etc.
(5) Patient suffering from uncontrolled Diabetes, Tuberculosis, Hypertension, Malignancy, and/or any other General Debilitating Health condition.
(6) Patient who needed surgical intervention (Polyp, etc.)
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| The improvement in patients will be assessed on the basis of relief in the signs and symptoms of the disease. For this purpose main signs and symptoms were given score according to their severity. |
(DAY 0),(DAY 15),(DAY 45) |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Improvement in MSQ: MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE and VAS(visual analogue scale). |
(DAY 0),(DAY 15),(DAY 45) |
|
|
Target Sample Size
|
Total Sample Size="45" Sample Size from India="45"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 2/ Phase 3 |
|
Date of First Enrollment (India)
|
01/03/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Need of the Study: Migraine, known as Ardhavabhedaka in Ayurveda, affects approximately 14.12% to 25.2% of the Indian population, yet safe and sustainable alternatives to conventional therapies remain limited. Traditional Ayurvedic instruments, such as the Dhuma Yantra, lack standardization, leading to inconsistent results due to variations in size and material. Furthermore, there is insufficient comparative evidence between Shirovirechanadi Dhumavarti and Anu Taila Nasya, despite the latter’s established efficacy in symptom alleviation ranging from 45.4% to 76%. There is a growing necessity to integrate Ayurvedic therapies such as Dhuma and Nasya with modern clinical protocols, particularly for managing Vata-Kapha conditions. Although Nasya is a relatively simple procedure, Dhumavarti protocols should be simplified further to ensure better patient compliance. Migraine continues to be a widespread condition that remains inadequately managed, and current treatments like analgesics are not suitable for long-term use. A significant portion of the population continues to suffer due to the limitations of existing treatment options. Therefore, simplifying Ayurvedic smoke therapy methods can potentially improve patient experience and outcomes. Rationality of the Study: A comparative evaluation is essential, as existing research highlights the multiple benefits of Dhuma Nasya therapy, such as relief from headaches, migraines, and nasal congestion, while also balancing Vata and Kapha doshas. However, the absence of standardized devices and the lack of systematic comparison with well-established therapies like Navan Nasya have created a gap in evidence-based Ayurvedic practice. This study aims to address this gap by conducting a rigorous clinical evaluation of an improved Dhuma Yantra in comparison with proven traditional methods. Objectives: Primary: Development and validation of a standardized Dhuma Yantra. Evaluation of whether Anu Taila Nasya provides superior clinical outcomes in symptom reduction, assessed using a standardized scoring system, compared to Dhuma Nasya with Shirovirechanadi Dhumavarti administered through the classical method and prototype Dhuma Yantra. Secondary: Assessment of the impact of headaches on daily life using the HIT-6 questionnaire. Improvement in the Migraine Specific Quality of Life Questionnaire (MSQ) and Visual Analogue Scale (VAS). Methodology: Type of Study: Triple-arm interventional clinical trial. Study Design: Randomized comparative clinical trial. Study Duration: Two and a half years. Study Site: Patients attending the Panchakarma OPD and IPD at AIIA who meet the diagnostic criteria will be recruited. Sampling Procedure: Probability sampling. Randomization: Simple randomization. Blinding or Masking: Open-label study. |